Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Research & Development (2018 - 2025)

Arcturus Therapeutics Holdings' Research & Development history spans 8 years, with the latest figure at $24.5 million for Q4 2025.

  • For Q4 2025, Research & Development fell 44.09% year-over-year to $24.5 million; the TTM value through Dec 2025 reached $112.2 million, down 42.5%, while the annual FY2025 figure was $112.2 million, 42.5% down from the prior year.
  • Research & Development reached $24.5 million in Q4 2025 per ARCT's latest filing, up from $23.3 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $58.7 million in Q2 2024 to a low of $23.3 million in Q3 2025.
  • Average Research & Development over 5 years is $41.1 million, with a median of $41.5 million recorded in 2024.
  • Peak YoY movement for Research & Development: surged 532.18% in 2021, then tumbled 49.58% in 2025.
  • A 5-year view of Research & Development shows it stood at $32.6 million in 2021, then decreased by 17.32% to $27.0 million in 2022, then soared by 35.73% to $36.6 million in 2023, then grew by 19.55% to $43.8 million in 2024, then plummeted by 44.09% to $24.5 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Research & Development are $24.5 million (Q4 2025), $23.3 million (Q3 2025), and $29.6 million (Q2 2025).